title: Dabigatran: will it change clinical practice?
abstract: Dabigatran (Pradaxa) is a new oral anticoagulant approved in the United States for the primary prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation. It offers clinicians an alternative to warfarin (Coumadin), and it has received considerable interest because of its convenience of use, clinical efficacy, and safety profile. However, it is more expensive, and this may limit its widespread use.
authors.affiliation: FACC, Department of Cardiovascular Medicine, Cleveland Clinic, OH 44195, USA.
authors.forename: Siddharth A
authors.initials: SA
authors.lastname: Wartak
authors.forename: John R
authors.initials: JR
authors.lastname: Bartholomew
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D004617:Embolism / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control*; D014481:United States; D014859:Warfarin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran